News

Pressure BioSciences, Inc. to Host Business and Financial Update on Thursday, June 20th at 4:30pm ET

NOTE CHANGE IN DATE OF UPDATE CALL TO THURSDAY JUNE 20thCANTON, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences,…

5 months ago

Upswing Health and Hinge Health Partner to Address Care for Acute MSK Injuries for Joint Clients

STAMFORD, Conn., June 18, 2024 (GLOBE NEWSWIRE) -- Upswing Health, the surgeon-founded virtual orthopedic care company, today announced a partnership…

5 months ago

Daxor Corporation to Showcase the Benefits of BVA-100™ Guided-Care at the American Association of Heart Failure Nurses (AAHFN) 20th Annual Meeting

Oak Ridge, TN, June 18, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement…

5 months ago

CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field…

5 months ago

Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 for the Treatment of Chronic Hepatitis B Virus Infection

– Phase 1b study will evaluate safety, pharmacokinetic and efficacy endpoints in participants with chronic hepatitis B virus infection with…

5 months ago

CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec

- First Patient Dosed in Expanded Access Program and Enrollment Ongoing -IRVINE, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CG…

5 months ago

Annovis Bio Highlights New Alzheimer’s Data at the Alzheimer’s Association International Conference® 2024

MALVERN, Pa., June 18, 2024 (GLOBE NEWSWIRE) -- via IBN -- Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a…

5 months ago

Analysis of INPEFA® (Sotagliflozin) Cost-Effectiveness Published in JACC: Heart Failure, the Peer-Reviewed Journal of the American College of Cardiology

New analysis of the pivotal Phase 3 SOLOIST-WHF trial demonstrates INPEFA cost-effectiveness Findings consistent with another study recently published in…

5 months ago

FibroGen to Host Part II of Virtual KOL Investor Event Series to Review FG-3246 Development Program in Metastatic Castration-Resistant Prostate Cancer on June 26, 2024

SAN FRANCISCO, June 18, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced it will host the second part…

5 months ago